• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Aubert Paul

    5/4/23 6:00:02 PM ET
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $BPTH alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Aubert Paul

    (Last) (First) (Middle)
    6111 S. TRACE DRIVE

    (Street)
    MAGNOLIA TX 77354

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    BIO-PATH HOLDINGS INC [ BPTH ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    05/02/2023
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Rule 10b5-1(c) Transaction Indication

      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Common Stock Option (right to buy) $1.39 05/02/2023 A 10,000 (1) 05/02/2033 Common Stock 10,000 $0 10,000 D
    Explanation of Responses:
    1. This option vests over a one-year period, with the shares vesting in equal monthly increments equal to one-twelfth (1/12) of the 10,000 shares, based on continuing service to Bio-Path Holdings, Inc.
    /s/ Paul D. Aubert 05/04/2023
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $BPTH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BPTH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BPTH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Life Sciences Investor Forum: Now Available for Online Viewing

      NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Investor Forum, held June 11th and 12th are now available for online viewing. REGISTER AND VIEW PRESENTATIONS The company presentations will be available 24/7 for 90 days. Investors, advisors, and analysts may downloadinvestor materials from the company's resource section. Select companies are accepting 1x1 management meeting requests through June 17. June 11th PresentationTicker(s)Nika Pharmaceuticals(OTCQB:NIKA)Tivic Health Systems Inc.(NASDAQ:TIVC)Ad

      6/13/25 8:35:00 AM ET
      $ATNM
      $BPTH
      $COCH
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
      Medical/Nursing Services
    • Life Sciences Investor Forum Agenda Announced for June 11th-12th

      NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum June 11th & 12th. This event is co-hosted by Zacks Small Cap Research. Individual investors, institutional investors, advisors, and analysts are invited to attend. REGISTER HERE It is recommended that investors pre-register and run the online system check to expedite participation and receive event updates. There is no cost to log-in, attend live presentations, or schedule 1x1 meetings with management. "The life sciences sector is driving breakthrough innovation, and we're proud to give these pioneering co

      6/10/25 2:38:09 PM ET
      $ATNM
      $BPTH
      $COCH
      $IMNN
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Industrial Specialties
      Medical/Nursing Services
    • Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum

      HOUSTON, June 09, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTC:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced Peter Nielsen, Chief Executive Officer, will present a corporate overview at the Life Sciences Virtual Investor Forum on Thursday, June 12 at 12:00 p.m. ET. A live stream of the presentation will be available here and on the Investor Relations section of Bio-Path's website, where it will be archived for approximately 90 days. About Bio-Path Holdings, Inc. Bio-Path is a biotechnology company developing DNAbilize®, a

      6/9/25 7:00:00 AM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPTH
    Financials

    Live finance-specific insights

    See more
    • Bio-Path Holdings Provides Clinical and Operational Update

      HOUSTON, June 03, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® liposomal delivery and antisense technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced highlights from the recent clinical development and operational update conference call and webcast held May 26, 2025. An archived webcast of the event can be accessed here. "Our business model centers around generating new drug candidates from our DNAbilize® platform and licensing them for final development and commercialization with partners that have expertise and scale to successfully bring them to market," sa

      6/3/25 7:00:00 AM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bio-Path Holdings to Host Corporate Update Conference Call on May 29, 2025

      HOUSTON, May 22, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH) a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced that it will host a live conference call and audio webcast on Thursday, May 29, 2025 at 8:30 a.m. ET to provide a comprehensive business overview. To access the live conference call, please call (844) 481-3014 (domestic) or (412) 317-1879 (international) at least five minutes prior to the start time. A live audio webcast of the call will also be available on the Presentations section of the Company's website, www.biopathho

      5/22/25 4:30:00 PM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bio-Path Holdings Reports Full Year 2024 Financial Results

      HOUSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (OTCQB:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer and obesity drugs, today announced its financial results for the year ended December 31, 2024 and provided an update on recent corporate developments. "We are merely touching the tip of the iceberg in terms of realizing the potential of our DNAbilize® platform to change the treatment paradigm in both obesity and oncology," said Peter Nielsen, President and Chief Executive Officer of Bio-Path Holdings. "Throughout the last year, we built on the bo

      3/28/25 7:00:00 AM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Bio-Path Holdings Inc.

      SC 13G/A - BIO-PATH HOLDINGS, INC. (0001133818) (Subject)

      11/13/24 11:15:11 AM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Bio-Path Holdings Inc.

      SC 13G/A - BIO-PATH HOLDINGS, INC. (0001133818) (Subject)

      11/6/24 4:52:04 PM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Bio-Path Holdings Inc.

      SC 13G - BIO-PATH HOLDINGS INC (0001133818) (Subject)

      4/3/24 5:44:32 PM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPTH
    Leadership Updates

    Live Leadership Updates

    See more
    • Bio-Path Holdings Appoints Aline Sherwood to Board of Directors

      HOUSTON, April 06, 2022 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced the appointment of Aline Sherwood to its Board of Directors on March 31, 2022. Ms. Sherwood replaced Martina Molsbergen, who stepped down from the Board of Directors on February 14, 2022. "We are delighted to welcome Aline to the Bio-Path Board of Directors. With her extensive background in biotechnology communications, Aline synthesizes complex science into compelling messaging, which is instrumental in guiding our communications

      4/6/22 7:00:00 AM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Sherwood Aline

      4 - BIO-PATH HOLDINGS, INC. (0001133818) (Issuer)

      8/1/24 6:14:31 PM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Aubert Paul

      4 - BIO-PATH HOLDINGS, INC. (0001133818) (Issuer)

      8/1/24 6:10:56 PM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Cleaver Heath

      4 - BIO-PATH HOLDINGS, INC. (0001133818) (Issuer)

      8/1/24 6:07:55 PM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPTH
    SEC Filings

    See more
    • SEC Form 253G3 filed by Bio-Path Holdings Inc.

      253G3 - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)

      6/2/25 4:35:21 PM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form QUALIF filed by Bio-Path Holdings Inc.

      QUALIF - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)

      5/30/25 12:15:10 AM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 1-A/A filed by Bio-Path Holdings Inc.

      1-A/A - BIO-PATH HOLDINGS, INC. (0001133818) (Filer)

      5/16/25 4:15:19 PM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $BPTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital initiated coverage on Bio-Path

      Roth Capital initiated coverage of Bio-Path with a rating of Buy

      3/11/21 7:29:52 AM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ROTH Capital initiated coverage on Bio-Path with a new price target

      ROTH Capital initiated coverage of Bio-Path with a rating of Buy and set a new price target of $13.00

      3/11/21 7:25:18 AM ET
      $BPTH
      Biotechnology: Pharmaceutical Preparations
      Health Care